Valneva (VALN) Q2 2026 earnings review
Lyme Success Overshadowed by Commercial Portfolio Collapse
Valneva has secured its long-awaited catalyst: positive Phase 3 data for its Lyme disease vaccine. However, this milestone is severely overshadowed by a commercial collapse in its existing portfolio. H1 2026 total product sales decelerated 30% YoY to €64.0M. The launch of the IXCHIQ chikungunya vaccine has essentially failed in the travel market, forcing a massive -315% gross margin for the segment due to €14.2M in cancellation and impairment fees. With total product margins crashing to 23%, net loss widened to €63.3M. The company is now rapidly restructuring—cutting 10-15% of staff and selling its Nantes site—to preserve its €121.5M cash runway until a potential Lyme commercialization in 2027. Management reaffirmed FY26 revenue guidance, which implies a steep and highly risky acceleration in H2.
🐂 Bull Case
The Phase 3 VALOR trial for LB6V achieved its primary endpoints with >70% efficacy. If approved, Valneva stands to receive massive milestone payments and royalties from Pfizer in an untapped market.
The global restructuring plan aims to reduce 2026 operating expenses by 25-35%. Selling the Nantes site (€6.2M) and cutting 10-15% of the workforce buys essential time.
🐻 Bear Case
Total product gross margin plummeted to 23.0% from 59.8% YoY. DUKORAL and IXIARO margins are deteriorating due to failed batch costs, idle capacity, and lower volumes.
The chikungunya vaccine generated only €4.4M in sales against €14.2M in write-offs and cancellation fees. The pivot away from the travel market to endemic regions is proving costly and slow.
⚖️ Verdict: 🔴
Bearish. The Lyme clinical success is a massive long-term win, but the immediate commercial reality is bleak. Bleeding cash, collapsing margins, and a heavy reliance on a dramatic H2 sales recovery make the near-term setup highly precarious.
Key Themes
IXCHIQ Commercial Disaster
The chikungunya vaccine launch is reversing course dramatically. Sales fell to €4.4M in H1 2026, and the segment posted a shocking -315.1% gross margin. Management was forced to record €9.7M in cancellation fees for external manufacturing commitments and a €4.5M non-cash impairment for excess inventory. The pivot to endemic territories (like the Brazil pilot program) is entirely failing to offset the loss of the travel market.
Lyme Vaccine (LB6V) Regulatory Pathway
The single largest catalyst for the company is intact. Following positive Phase 3 VALOR results in March 2026 showing >70% efficacy, Pfizer is engaging regulatory authorities. Regulatory decisions are expected within the next 12 months. This represents Valneva's ultimate bridge to profitability.
Core Portfolio Margin Compression
The gross margin collapse isn't isolated to IXCHIQ. DUKORAL margins crashed from 52.9% to 24.7% due to inventory revaluation and higher failed batch costs. IXIARO margins slipped from 65.5% to 56.4% due to lower volumes and adverse manufacturing cost changes. Unallocated manufacturing costs (idle capacity) jumped to €9.4M from €6.0M.
Restructuring to Protect the Runway
Management is pulling the emergency brake on spending. The new global restructuring initiative targets a 25-35% reduction in 2026 OpEx versus 2025. This includes a 10-15% global workforce reduction, reprioritization of R&D, and the sale of the Nantes facility to the local government for €6.2M. Execution here is vital to stretch the current €121M cash balance.
Macro Geopolitical Headwinds Hitting Travel
Management explicitly blamed the 'continued adverse impact of the geopolitical environment on travel' for sluggish vaccine uptake. Alongside the transition to new distributor CSL Seqirus in Germany—which temporarily halted DUKORAL shipments—the macro environment is compounding Valneva's internal execution issues.
Illusion of Cash Strength
Management touted a 'strong cash position' of €121.5M, up from €109.7M at the end of 2025. However, this contradicts the operational reality: operations burned €13.7M in H1. The entire cash increase was artificially propped up by a dilutive €37M reserved offering completed in Q2. Without this raise, cash would have declined significantly.
Other KPIs
Decelerating. Net loss widened sharply from €(20.8) million in H1 2025. The core driver was the collapse in gross profit (dropping from €50.4M to €6.3M) due to the IXCHIQ write-offs and lower overall sales volumes, completely wiping out the modest savings in R&D and Marketing expenses.
Reversing sharply from €(6.0) million in the prior year. More than 50% of the company's operating loss was generated by the struggling IXCHIQ segment alone.
Guidance
Accelerating significantly in the second half. By reaffirming this guidance despite only hitting €64.0M in H1, management implies H2 product sales of €71M to €86M (midpoint €78.5M). This represents an implied H2 YoY growth of ~17% versus H2 2025, a massive and risky reversal from the 30% YoY contraction just witnessed in H1.
Reaffirmed. This includes €10M in expected other revenues (collaborations, licensing), down significantly from the historical peak when the Serum Institute of India contract was active.
Key Questions
H2 Execution Risk
Reaffirming the €135-€150M product sales guidance implies a massive sequential acceleration to roughly €78M in H2. Given the distributor transition drag and IXCHIQ's collapse, what specific mechanics give you confidence this steep H2 ramp is achievable?
IXCHIQ Bottom
You recorded €14.2M in IXCHIQ write-offs and cancellation fees as you pivot away from the travel market. Are we entirely cleared of external manufacturing commitments, or should we expect lingering cancellation fees in H2?
DUKORAL Margin Recovery
DUKORAL margins crashed from 53% to 25% due to failed batches and lower volume. How much of this is structural versus a one-time hit, and where do you expect this margin to land in 2027?
Restructuring Mechanics
Regarding the targeted 25-35% OpEx reduction for 2026, how much of these savings are structurally tied to the €6.2M sale of the Nantes site versus the 10-15% headcount reductions?